December 29, 2011 — A budesonide/formoterol pressurized metered dose inhaler (pMDI) reduced chronic obstructive pulmonary disease (COPD) exacerbations more effectively than a formoterol dry powder ...
AstraZeneca will discontinue the production of PULMICORT® (budesonide) 100 and 200 µg/dose HFA pMDI (pressurised metered dose inhaler) due to complex manufacturing issues related to technical aspects ...
Switching asthma patients from a pressurised metered dose inhaler (pMDI) to a dry powder inhaler (DPI) for maintenance therapy more than halves their carbon footprint without loss of asthma control, ...
The AERISTO trial results did not affect approval but could make it harder to market the drug in a competitive market where GSK’s Anoro (umeclidinium+vilanterol) is a benchmark treatment. AZ hopes to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results